Quell Reports Successful CES 2019
January 16 2019 - 01:00PM
NeuroMetrix (Nasdaq: NURO) today announced a successful CES 2019,
the world’s largest and most influential technology event, which
took place January 8 – 11 in Las Vegas. Highlights of the
week-long event include:
- Quell® 2.0 was named a CES® 2019 Innovation Awards Honoree in
the Fitness, Sports and Biotech product category, recognizing the
company’s innovative application of AI + neurotechnology to manage
chronic pain.
- NeuroMetrix President and CEO, Shai Gozani was a speaker at the
Digital Health Summit at CES, focusing on the continued advances in
healthcare.
- PC Magazine picked Quell 2.0 as one of the
"Best Wearables at CES 2019".
- The Washington Times named Quell 2.0 a
“Technological Option to Opioids”.
- Digital Trends included Quell 2.0 in their
list of “The best CES 2019 health gadgets”.
- Jennifer Jolly, technology expert for USA Today, and The Today
Show included Quell 2.0 in her TV broadcast from the floor of
CES.
For a recap of Quell at CES and a preview of coming
innovation, visit Quell on YouTube.About CES
CES® is the world's gathering place for all who thrive on the
business of consumer technologies. It has served as the proving
ground for innovators and breakthrough technologies for 50 years -
the global stage where next-generation innovations are introduced
to the marketplace. As the largest hands-on event of its kind, CES
features all aspects of the industry. Owned and produced by the
Consumer Technology Association (CTA)™, it attracts the world's
business leaders and pioneering thinkers. The CES Innovation Awards
are based upon descriptive materials submitted to the judges. CTA
did not verify the accuracy of any submission or of any claims made
and did not test the item to which the award was given.
About Quell
Quell is an advanced, wearable technology for treating chronic
pain. It can be worn during the day while active and at night while
sleeping. Quell is drug-free and has been cleared by the FDA for
treatment of chronic pain without a prescription. Quell has been
shown in multiple clinical studies to relieve chronic pain and, in
a published study, 4 out of 5 users reported improvement in chronic
pain. Quell users can personalize and manage therapy
discreetly via the Quell app. Quell also offers health
tracking relevant to chronic pain sufferers including pain, sleep,
activity, and gait. Quell users can synchronize their data with the
Quell Health Cloud™, which provides customized feedback and powers
one of the world’s largest chronic pain databases. Quell is
available online and through select retailers. Visit
QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare
company combining neurostimulation and digital medicine to address
chronic health conditions including chronic pain, sleep disorders,
and diabetes. The Company has two primary products. Quell is an
over-the-counter wearable therapeutic device for chronic pain.
DPNCheck® is a rapid point-of-care test for diabetic neuropathy
which is the most common long-term complication of Type 2 diabetes.
For more information, please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial OfficerNeurometrix.ir@neurometrix.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/d91c72e5-75f6-4cf8-b3d7-acfa35f689ce
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Feb 2024 to Mar 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2023 to Mar 2024